Mineralys Therapeutics MLYS 深 滬
已收盤 11-06 16:00:00 美东时间
15.33
+0.090
+0.59%
華盛通- 最 高15.645
- 今 開15.23
- 成交量 133.54万股
- 最 低 14.91
- 昨 收 15.24
- 總市值 13.55亿
- 52周最高 45.615
- 市盈率 靜 --
- 換手率 1.51%
- 52周最低 14.91
- 委 比 -38.93%
- 總股本 8840.69万
- 歷史最高 47.65
- 量 比 0.43
- 振 幅 4.82%
- 歷史最低 5.85
- 每 手 1
- 風險率 5.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics granted stock options and restricted stock units to a new non-executive employee under its 2025 Employment Inducement Incentive Award Plan. The stock option award covers 14,880 shares, vesting over four years, with 25% vesting on the first anniversary and monthly thereafter. The restricted stock unit award covers 11,160 shares, vesting 25% annually over four years. Both awards are subject to continued employment and comply ...
11-06 13:00
Mineralys Therapeutics Q3 2026 Earnings Call Transcript
Mineralys Therapeutics (NASDAQ:MLYS) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/ap...
11-05 06:19
Mineralys Therapeutics收跌14.47%，成交额7414.52万美元
11月3日，Mineralys Therapeutics（MLYS）收跌14.47%，报15.55美元，成交额7414.52万美元，市值13.75亿美元。 行情...
11-03 06:35
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Mineralys Therapeutics announced that the Phase 2 Explore-CKD trial of lorundrostat met its primary endpoint, showing a statistically significant reduction in systolic blood pressure (9.3 mmHg vs. 1.8 mmHg with placebo) and a 41.5% reduction in serum aldosterone in participants with uncontrolled hypertension, CKD, and albuminuria. Lorundrostat also significantly reduced urinary protein loss, with a 30.5% decrease in UACR. The results highlight it...
10-28 11:05
Mineralys Therapeutics收涨0.05%，成交额1629.72万美元
10月27日，Mineralys Therapeutics（MLYS）收涨0.05%，报20.56美元，成交额1629.72万美元，市值18.18亿美元。 行情...
10-27 05:29
Mineralys Therapeutics expands board with new independent directors
Mineralys Therapeutics, Inc. ( ($MLYS) ) has issued an update. On October 16, 2...
10-20 04:59
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics appoints Kristine Peterson and Lonnel Coats to its Board of Directors, adding extensive commercial and product launch experience ahead of the December 22 PDUFA target date for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both executives bring deep expertise in launching and commercializing therapies, particularly in cardiovascular and metabolic disease. Peterson, with over three decades in biopharma...
10-19 20:05
Mineralys Therapeutics收跌6.19%，成交额2420.66万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:31
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-12 21:20
